Study Results for IMPAACT P1078 Presented at CROI 2018. IMPAACT Network News

Date: 03/07/2018

Publication:

IMPAACT Network News

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is delighted to announce the presentation of the study results and important findings from IMPAACT P1078 (TB APPRISE), a phase IV, randomized, double-blind, placebo-controlled trial to evaluate the safety of immediate versus deferred isoniazid preventive therapy (IPT) among HIV-infected women in high tuberculosis (TB) incidence settings, at the 2018 annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, Massachusetts. 

Access Full Article

Clinical Trials

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More